Drug Profile
Mavoglurant - STALICLA
Alternative Names: AFQ-056; STP-7Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Novartis
- Class Alkynes; Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Esters; Indoles; Neuropsychotherapeutics; Nitriles; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Chorea; Cocaine-related disorders; Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux; Obsessive-compulsive disorders; Smoking withdrawal
Most Recent Events
- 22 Feb 2024 Stalicla in collaboration with National Institute on Drug Abuse (NIDA) plans a phase I drug-drug interaction trial (In volunteers, Treatment-naive) in Cocaine use disorder (PO) in March 2024 (NCT06273540)
- 16 Jan 2024 STALICLA and National Institute on Drug Abuse plans a phase-III trial for Substance-related disorders in 2025
- 18 Nov 2023 STALICLA plans a phase II trial for Alcoholism in USA (PO) (NCT06136195)